Metabolic consequences of securin disruption
Metabolic consequences of securin disruption
批准号:
6833420
负责人:
SHLOMO MELMED
金额:
$32.36万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-03-01 至 2008-01-31
中文摘要
超出所提供的空间。细胞周期依赖的安全蛋白通过抑制分离功能调节姐妹染色单体的分离。我们从大鼠垂体肿瘤细胞中分离并鉴定了垂体肿瘤转化基因(PTTG), PTTG在功能上与酵母安全蛋白同源。PTTG在几种肿瘤类型中过表达,在一些正常的复制组织(包括睾丸、淋巴细胞)中也过表达。当PTTG基因被删除后,敲除的小鼠能够存活、生育,并表现出脾脏和睾丸发育不全和血小板减少症。令人惊讶的是,6个月后,雄性PTTG -/-小鼠体重没有增加,出现严重的高血糖症、低胰岛素血症和低瘦素血症,胰岛素敏感性完好无损。在初步实验中,胰岛胰岛素免疫反应性降低,胰腺β细胞出现发育不良,没有证据表明自身免疫性胰岛受损伤。本课题旨在通过评估胰岛素的转录、分泌和作用、脂肪细胞激素的调节以及评估胰腺β细胞的发育、复制和胰腺再生来研究哺乳动物securin在胰腺β细胞功能中的作用。由于缺乏安全蛋白的糖尿病仅限于雄性小鼠,完整或性腺去角质的PTTG -/-动物将接受性类固醇治疗,并评估其对血糖和胰腺功能的影响。这些研究强调了细胞周期调节蛋白在胰腺β细胞发育和功能中的作用。在这种独特的遗传背景下,这些实验确定了securin是胰腺细胞功能的关键因素,并为糖尿病的新单基因病因提供了见解。网站性能 ======================================== 节结束 ===========================================
英文摘要
EXCEED THE SPACE PROVIDED. Cell cycle-dependent securin proteins regulate sister chromatid separation by inhibiting separin function. We isolated and have characterized pituitary tumor transforming gene (PTTG) from rat pituitary tumor cells, and PTTG is functionally homologous to yeast securin. PTTG is overexpressed in several tumor types, and also in some normal replicating tissues (including testis, lympocytes). When the PTTG gene was deleted, resultant knockout mice were viable, fertile and exhibited splenic and testicular hypoplasia and thrombocytopenia. Surprisingly, after 6 months, male PTTG -/- mice do not gain weight, develop profound hyperglycemia, hypo-insulinemia, and hypo-leptinemia with intact insulin sensitivity. In preliminary experiments, pancreatic beta cells apear hypoplastic with diminished islet insulin immunoreactivity, and no evidence for auto-immune islet involvement. This proposal aims to study the role of mammalian securin in pancreatic beta cell function by assessing insulin transcription, secretion and action, regulation of adipocyte hormones and assessment of pancreatic beta cell development and replication, and pancreatic regeneration. As securin-deficient diabetes is restricted to male mice, intact or gonadectomized PTTG -/- animals will be treated with sex steroids, and their impact on glycemia and pancreatic function assessed. These studies highlight the role of a cell cycle-regulating protein in pancreatic beta cell development and function. In the context of this unique genetic background, these experiments identify securin as a critical factor for pancreatic cell function and provide insights into a novel monogenic cause of diabetes. PERFORMANCE SITE ========================================Section End===========================================
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Ph 2 Multicenter study of seliciclib for Cushing Disease IND 120,848 (10/10/2017)
-
批准号:10003845
-
项目类别:
-
资助金额:$46.78万
-
财政年份:2018
-
负责人:SHLOMO MELMED
-
依托单位:
Mechanisms for GH action on epithelial cells
-
批准号:10578571
-
项目类别:
-
资助金额:$36.74万
-
财政年份:2018
-
负责人:SHLOMO MELMED
-
依托单位:
Mechanisms for GH action on epithelial cells
-
批准号:9893867
-
项目类别:
-
资助金额:$38.25万
-
财政年份:2018
-
负责人:SHLOMO MELMED
-
依托单位:
Treatment of pituitary Cushing disease with a selective CDK inhibitor, R-roscovit
-
批准号:8773516
-
项目类别:
-
资助金额:$23.44万
-
财政年份:2014
-
负责人:SHLOMO MELMED
-
依托单位:
Cedars-Sinai Biobank and Translational Research Core Facility (CS-BRCF)
-
批准号:7935157
-
项目类别:
-
资助金额:$955.29万
-
财政年份:2010
-
负责人:SHLOMO MELMED
-
依托单位:
PITUITARY TUMOR SURVEILLANCE: PATHOGENETIC CORRELATION
-
批准号:7606126
-
项目类别:
-
资助金额:$0.08万
-
财政年份:2007
-
负责人:SHLOMO MELMED
-
依托单位:
MECHANISMS FOR PITUITARY TUMORIGENESIS
-
批准号:7606124
-
项目类别:
-
资助金额:$0.09万
-
财政年份:2007
-
负责人:SHLOMO MELMED
-
依托单位:
MECHANISMS FOR PITUITARY TUMORIGENESIS
-
批准号:7376014
-
项目类别:
-
资助金额:$0.22万
-
财政年份:2005
-
负责人:SHLOMO MELMED
-
依托单位:
PITUITARY TUMOR SURVEILLANCE: PATHOGENETIC CORRELATION
-
批准号:7376016
-
项目类别:
-
资助金额:$0.22万
-
财政年份:2005
-
负责人:SHLOMO MELMED
-
依托单位:
PITUITARY TUMOR SURVEILLANCE: PATHOGENETIC CORRELATION
-
批准号:7206322
-
项目类别:
-
资助金额:$0.18万
-
财政年份:2004
-
负责人:SHLOMO MELMED
-
依托单位:
MECHANISMS FOR PITUITARY TUMORIGENESIS
-
批准号:7206320
-
项目类别:
-
资助金额:$0.18万
-
财政年份:2004
-
负责人:SHLOMO MELMED
-
依托单位:
Metabolic consequences of securin disruption
-
批准号:7008190
-
项目类别:
-
资助金额:$31.6万
-
财政年份:2003
-
负责人:SHLOMO MELMED
-
依托单位:
Metabolic consequences of securin disruption
-
批准号:6599784
-
项目类别:
-
资助金额:$32.36万
-
财政年份:2003
-
负责人:SHLOMO MELMED
-
依托单位:
Metabolic consequences of securin disruption
-
批准号:7172931
-
项目类别:
-
资助金额:$30.68万
-
财政年份:2003
-
负责人:SHLOMO MELMED
-
依托单位:
Pituitary Tumor Surveillance: Pathogenetic Correlation
-
批准号:7042064
-
项目类别:
-
资助金额:$1.41万
-
财政年份:2003
-
负责人:SHLOMO MELMED
-
依托单位:
Metabolic consequences of securin disruption
-
批准号:6710585
-
项目类别:
-
资助金额:$32.36万
-
财政年份:2003
-
负责人:SHLOMO MELMED
-
依托单位:
Mechanisms for Pituitary Tumorigenesis
-
批准号:7042061
-
项目类别:
-
资助金额:$1.41万
-
财政年份:2003
-
负责人:SHLOMO MELMED
-
依托单位:
Information Technology for Human Subjects Protection
-
批准号:6591413
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2002
-
负责人:SHLOMO MELMED
-
依托单位:
Gordon Research Conference on Prolactin
-
批准号:6623298
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2002
-
负责人:SHLOMO MELMED
-
依托单位:
Gordon Research Conference on Prolactin
-
批准号:6831175
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2002
-
负责人:SHLOMO MELMED
-
依托单位:
国内基金
海外基金
Exposing Verifiable Consequences of the Emergence of Mass
-
批准号:12135007
-
项目类别:重点项目
-
资助金额:313万元
-
批准年份:2021
-
负责人:Craig Darrian Roberts
-
依托单位:
Accretion variability and its consequences: from protostars to planet-forming disks
-
批准号:12173003
-
项目类别:面上项目
-
资助金额:60万元
-
批准年份:2021
-
负责人:沈雷歌
-
依托单位:
Consequences of MALT1 mutation for B cell tolerance
-
批准号:32100719
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:James Qun Wang
-
依托单位: